默沙东(MRK.US)盘初一度跌约3.8%，最低触及83.3美元，创近两周新低。 消息面上，默沙东第三季业绩喜忧参半，调整后每股盈利为2.58美元，营收为172.8亿美元，均超预期。癌症免疫疗法Keytruda收入同比增长10%至81.4亿美元，略低于预期的82.4亿美元。公司下调全年盈利预期，以反映预计关税成本和其他项目下降，目前预计调整后每股盈利将介于8.93至8.98美元之间，低于早前预期为8.87美元至8.97美元。(格隆汇)
默沙东(MRK.US)盘初一度跌约3.8%，最低触及83.3美元，创近两周新低。 消息面上，默沙东第三季业绩喜忧参半，调整后每股盈利为2.58美元，营收为172.8亿美元，均超预期。癌症免疫疗法Keytruda收入同比增长10%至81.4亿美元，略低于预期的82.4亿美元。公司下调全年盈利预期，以反映预计关税成本和其他项目下降，目前预计调整后每股盈利将介于8.93至8.98美元之间，低于早前预期为8.87美元至8.97美元。(格隆汇)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.